



I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Box PGPUB Drawings, Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: September 13, 2001

By: Carol A. See  
Carol A. See

#4150 1652  
9/22/01 RECEIVED  
SEP 21 2001

TECH CENTER 1600/2900

PATENT  
Docket No. GC382-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Attn: Drafting Branch  
David A. Estell ) Group Art Unit: 1652  
Serial No. 09/462,845 ) Examiner: Yong Pak  
Filed: January 13, 2000 )  
For: Proteases from Gram-Positive Organisms)

SUBMISSION OF FORMAL DRAWINGS

Box PGPUB Drawings  
Commissioner for Patents  
Washington, D.C. 20231

Attn: Official Draftsperson


Sir:

In response to the Attachment for PTO-948 mailed August 13, 2001, please substitute the enclosed sixteen (16) sheets of formal drawings for the informal drawings previously filed with respect to the above-identified patent application. Should the enclosed drawings require changes, it is respectfully requested that the Patent and Trademark Office notify the undersigned attorney of same.

Respectfully submitted,

Victoria L. Boyd  
Victoria L. Boyd  
Registration No. 43,510

Date: Sept 13, 2001  
Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-7615  
Fax: 650-845-6504



<b>Notice to Comply</b>	Application No.	Applicant(s)
	Examiner	Art Unit
<b>NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES</b>		
Applicant must file the items indicated below within the time period set by the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
<input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
<input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
<input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
<input type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
<input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
<input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
<input type="checkbox"/> 7. Other:		
<b>Applicant Must Provide:</b>		
<input type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
<input type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
<input type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support Technical Assistance.....703-287-0200 To Purchase PatentIn Software.....703-306-2600		
<b>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</b>		

#44062  
A/221D  
BOX SE

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Box Sequence, Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: September 13, 2001

By: Carol A. See  
Carol A. See

PATENT  
Docket No. GC382-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

David A. Estell

Serial No. 09/462,845

Filed: January 13, 2000

For: Proteases from Gram-Positive Organisms)

) Group Art Unit: 1652

) Examiner: Yong Pak

**TRANSMITTAL LETTER FOR NOTICE TO COMPLY**

BOX SEQUENCE  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

In complete response to the Notice to Comply dated August 13, 2001  
enclosed please find:

- a Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e);
- Petition for a \_\_\_\_\_ Month Extension of Time;
- Assignment document, Form PTO-1595, and the \$40.00 Assignment Recording Fee;
- Associate Power of Attorney;
- Preliminary Amendment
- Statement of Sameness
- Paper copy of Sequence Listing (9 pages)
- Diskette copy of Sequence Listing

TECH CENTER 1600/2900

SEP 21 2001


RECEIVED

- Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e);
- Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy of Notice to be returned with response);
- Form PTO-1533 (copy of Notice to be returned with response); and
- Other: \_\_\_\_\_
- Charge \$\_\_\_\_\_ to Deposit Account No. 07-1048.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC382-US). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: Sept 13, 2001

  
Victoria L. Boyd  
Registration No. 43,510

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304  
Tel: 650-846-7615  
Fax: 650-845-6504